The Role of miR-21 in HER2-Positive Breast Cancer: A Comprehensive Review of Molecular Mechanisms, Biomarker Potential, and Therapeutic Implications
Journal of Cancer Biomoleculars and Therapeutics · 06.01.2026 · 3 (1) · 13-26
DOI: 10.62382/jcbt.v3i1.87 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cancer Biomoleculars and Therapeutics, online erschienen am 06.01.2026. Verfasst von Arefeh Zabeti Touchaei. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Breast cancer continues to be the most prevalent cancer affecting women, with Human Epidermal Growth Factor Receptor 2-positive (HER2-positive) breast cancer presenting particular difficulties because of its aggressive nature and resistance to treatments aimed at specific targets. MicroRNA-21 (miR-21) has been identified as an important factor in controlling HER2-related cancer development, significantly contributing to tumor growth, spread, and resistance to therapy. miR-21 is upregulated by approximately 2-5-fold in HER2-positive tumors compared to HER2-negative tumors, as reported in several clinical studies, correlating with advanced disease stage, lymph node metastasis, and resistance to HER2-targeted therapies. This study explores the multifaceted contributions of miR-21 to HER2-positive breast cancer biology, emphasizing its regulatory role in key oncogenic pathways, including PI3K/AKT/mTOR and MAPK/ERK. Here, discuss the possibility of miR-21 as a biomarker for diagnosis, prognosis, and monitoring therapeutic responses, particularly in liquid biopsy formats such as serum and extracellular vesicles (EVs). Furthermore, this review examines promising therapeutic strategies targeting the miR-21/HER2 axis, highlighting ongoing preclinical developments and future clinical applications. Despite the challenges in standardizing miR-21-based diagnostics and therapies, this review highlights the increasing potential of miR-21 as a therapeutic target, particularly in overcoming resistance to HER2-targeted treatments. This offers a promising pathway toward more personalized and effective options for HER2-positive breast cancer. However, while miR-21 shows significant promise, no therapies targeting miR-21 have been approved for clinical use, emphasizing the need for further research and clinical trials.
Zitieren
APA
Touchaei, A. Z. (2026). The Role of miR-21 in HER2-Positive Breast Cancer: A Comprehensive Review of Molecular Mechanisms, Biomarker Potential, and Therapeutic Implications. Journal of Cancer Biomoleculars and Therapeutics, 3(1), 13-26. https://doi.org/10.62382/jcbt.v3i1.87
Vancouver
Touchaei AZ. The Role of miR-21 in HER2-Positive Breast Cancer: A Comprehensive Review of Molecular Mechanisms, Biomarker Potential, and Therapeutic Implications. Journal of Cancer Biomoleculars and Therapeutics. 2026;3(1):13-26. doi:10.62382/jcbt.v3i1.87
BibTeX
@article{Touchaei2026,
author = {Touchaei, Arefeh Zabeti},
title = {The Role of miR-21 in HER2-Positive Breast Cancer: A Comprehensive Review of Molecular Mechanisms, Biomarker Potential, and Therapeutic Implications},
journal = {Journal of Cancer Biomoleculars and Therapeutics},
year = {2026},
volume = {3},
number = {1},
pages = {13--26},
doi = {10.62382/jcbt.v3i1.87}
}
EUVIMED